GPR183 and myeloid sarcoma: Interestingly, memory CD4+ T cells from MS patients treated with natalizumab display an increased Ebi2 expression and migration profile to 7α,25-OHC, suggesting an important role for Ebi2 and related oxysterol in human CD4 T cell migration in MS patients [84].